Personalized medicine

Egen Recognized as a Major Contender in Everest Group's Google Cloud Services Specialists PEAK Matrix® Assessment 2024

Retrieved on: 
Monday, March 18, 2024
Cloud, Google Cloud, Knowledge, Matrix, AI, Personalized medicine, Investment, Public sector, Engineering, Network equipment provider

NAPERVILLE, Ill., March 18, 2024 /PRNewswire/ -- Egen is recognized as a "Major Contender" in Google Cloud Services in the first Everest Group "Google Cloud Services Specialists PEAK Matrix® Assessment 2024" report.

Key Points: 
  • NAPERVILLE, Ill., March 18, 2024 /PRNewswire/ -- Egen is recognized as a "Major Contender" in Google Cloud Services in the first Everest Group "Google Cloud Services Specialists PEAK Matrix® Assessment 2024" report.
  • The report provides an objective, data-driven assessment of service and technology providers, classifying them into three categories: Leaders, Major Contenders, and Aspirants.
  • "Within the Google Cloud specialist landscape, Egen distinguishes itself by going beyond fundamental cloud services capabilities and deepening its focus on specific areas across data, AI, and platform.
  • These factors have contributed to its positioning as a Major Contender on Everest Group's Google Cloud Services Specialists PEAK Matrix® Assessment 2024," Chirayil said.

Leading-Edge Technologies, Data and Insights: Bio-IT World Conference & Expo Highlights the Drivers of Precision Medicine Innovation

Retrieved on: 
Thursday, March 14, 2024
Molecule, Learning Technology Partners, Personalized medicine, Organization, Conference, Innovation, Biotechnology, AstraZeneca, Partnering, Convention, Virtual humans, Data science, Drug discovery, RWE, Bias, Shape, Social media, Stargate Atlantis, RWD, Transformation, Bristol Myers Squibb, Digital twin, Student, LDN, Investment, Vacuum, RDN, Water, Machine learning, MD Anderson Cancer Center, Pharmaceutical industry

BOSTON, March 14, 2024 /PRNewswire/ -- Life science innovation doesn't happen in a vacuum. It results from leaders with complementary expertise partnering across organizations and countries to build on data, research, and case studies—all facilitated by leading-edge technologies.

Key Points: 
  • It results from leaders with complementary expertise partnering across organizations and countries to build on data, research, and case studies—all facilitated by leading-edge technologies.
  • From April 15-17, more than 3,000 pharmaceutical, biotechnology and IT leaders will gather for the 23rd annual Bio-IT World Conference & Expo in Boston to put this model into action.
  • "Precision medicine is at a tipping point as both scientific and computing capabilities explode," said Cindy Crowninshield, RDN, LDN, Executive Event Director.
  • This year, the Bio-IT World conference will focus on how to keep the creative pipeline flowing by bringing rising scientists into the fold.

Cardio Diagnostics Holdings, Inc. Announces Issuance of Second U.S. Patent for Compositions and Methods for Detecting Predisposition to Cardiovascular Disease

Retrieved on: 
Tuesday, March 5, 2024
Data Management, Health, Technology, Health Technology, Software, Artificial Intelligence, Cardiology, Cardiovascular disease, Personalized medicine, American Heart Association, Artificial intelligence, MD, Moyamoya disease, Patent, CVD, Entrepreneurship, Splenic infarction, Sudden death, European, Integration, University, Biomarker, CHD, Death, Risk assessment, Patient, Clinical trial, IP, Genomics, Heart, Diagnosis, Medicine, Pharmaceutical industry

This is the second U.S. patent being issued in this patent family.

Key Points: 
  • This is the second U.S. patent being issued in this patent family.
  • Patents in this patent family have also been issued in the European Union, China, India, and Australia.
  • According to the American Heart Association , cardiovascular disease (CVD) claims 2,552 lives daily in the United States, translating to a death every 34 seconds.
  • Heart disease, which includes heart attacks, has been the leading cause of death in the United States for 100 years.

Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress

Retrieved on: 
Monday, February 26, 2024
FDA, Health, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, PKD, Personalized medicine, EMA, Research, MAA, Investment, Marketing, Food, Arrhythmogenic cardiomyopathy, Circulation, BLA, PDUFA, Fanconi anemia, Conference, Safety, DCM, European Medicines Agency, Food and Drug Administration, Muscle weakness, Efgartigimod alfa, Pyruvate kinase deficiency, Patient, Disorder, Clinical trial, Medication, ACM, IND, AAV, CGMP, CMC, Priority review, Pharmaceutical industry

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today reported financial and operational results for the fourth quarter and year ended December 31, 2023.

Key Points: 
  • Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today reported financial and operational results for the fourth quarter and year ended December 31, 2023.
  • “I am pleased with the strong results Rocket delivered in 2023, as we closed another successful year of progress across all six disclosed gene therapy programs spanning our AAV cardiovascular and LV hematology portfolios,” said Gaurav Shah, M.D., Chief Executive Officer, Rocket Pharma.
  • Results from the study demonstrated the potential of RP-A601 as a gene therapy for patients with PKP2-ACM.
  • As of December 31, 2023, Rocket had cash, cash equivalents and investments of $407.5 million.

Technology Holdings Launches TH Healthcare & Life Sciences: Revolutionizing the Healthcare Investment Banking Landscape, leveraging over two decades of Healthcare Investment Banking transaction experience

Retrieved on: 
Tuesday, February 27, 2024
Banking, Asset Management, Professional Services, Finance, Personalized medicine, Marketing, Medicine, Health, Holding, Sale, Health care, NAMSA, Medtech, Automation, Salesforce, Marketing automation, Microsoft, Partner, Pharmaceutical industry

Technology Holdings , a global investment bank with offices in North America, Europe and the Asia-Pacific, proudly announces the launch of TH Healthcare & Life Sciences , its specialist healthcare investment banking division.

Key Points: 
  • Technology Holdings , a global investment bank with offices in North America, Europe and the Asia-Pacific, proudly announces the launch of TH Healthcare & Life Sciences , its specialist healthcare investment banking division.
  • TH Healthcare & Life Sciences will leverage Technology Holdings 23 years of healthcare transaction expertise, global reach with a presence in 9 countries and deep healthcare and life sciences sector knowledge.
  • TH Healthcare & Life Sciences leverages decades of relationships with key healthcare strategic buyers and private equity funds with a specialized, dedicated team of healthcare investment bankers allowing TH Healthcare & Life Sciences to strategically position healthcare and life sciences businesses and continue to achieve outstanding results for its clients.
  • “We are excited to announce the launch of TH Healthcare & Life Sciences, serviced by a dedicated team of healthcare investment bankers globally across 9 countries and 5 continents.

Caris Life Sciences Partners with Beat Childhood Cancer Research Consortium at Penn State University to Improve Outcomes for Pediatric Patients

Retrieved on: 
Tuesday, March 5, 2024
Therapy, Master of Science, Personalized medicine, Hospital, Oncology, Division, Research, Doctor of Philosophy, EVP, AI, Neoplasm, MD, Hematology, SVP, Blood, Science, Cancer, University, Vaccine, Data, Children's Miracle Network Hospitals, Feasibility, Health, Medicine, Patient, Pharmaceutical industry

IRVING, Texas, March 5, 2024 /PRNewswire/ -- Caris Life Sciences®(Caris), the leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition using molecular science and AI, today announced an ongoing collaboration with the Beat Childhood Cancer Research Consortium, a group of over 50 universities and children's hospitals, based at Penn State College of Medicine in Hershey, Pa., that offers a worldwide network of pediatric cancer clinical trials.

Key Points: 
  • Caris is now the molecular analysis partner for Beat Childhood Cancer Research Consortium studies.
  • As part of the collaboration to advance precision oncology and biomarker-driven research, Caris is now the molecular analysis partner for Beat Childhood Cancer Research Consortium studies.
  • In addition to tumor sequencing for new or recurring pediatric cancer patients, Caris and the Beat Childhood Cancer Research Consortium will also collaborate on research opportunities striving to advance pediatric patient care and improve outcomes.
  • "The Beat Childhood Cancer Research Consortium is excited to collaborate with Caris to expand our precision medicine program.

OncoHealth Expands Leadership Team with Appointments of Key New Executives

Retrieved on: 
Wednesday, February 21, 2024
CFO, The Advisory Board Company, Acquisition, Engineering, Pharmacy, Personalized medicine, Culver, Health, E&Y, Medicare, Patient, Warshaw, Erhardt, Cancer, Management

ATLANTA, Feb. 21, 2024 /PRNewswire-PRWeb/ -- OncoHealth®, the leading platform for managing the cost and complexity of cancer, today announced the appointments of Cliff Culver as chief operating officer (COO), Scott Warshaw as chief financial officer (CFO), and Brett Erhardt as chief strategy and growth officer.

Key Points: 
  • Culver brings significant experience operating, developing, launching, and scaling technology-enabled businesses across healthcare and biotech.
  • He previously held senior leadership positions at Precision Medicine Group, Science Exchange, and The Advisory Board Company.
  • Warshaw comes to OncoHealth from XiFin, where he served as chief strategy officer following its acquisition of OmniSYS.
  • As chief strategy and growth officer, Brett Erhardt will play a key role in executing corporate strategy across the organization and in spearheading continued growth opportunities for OncoHealth.

GE HealthCare and MedQuest Associates Collaborate to Provide Innovative Medical Device Technology and Digital Tools for Outpatient Imaging Centers

Retrieved on: 
Thursday, February 8, 2024
Biotechnology, Medical Devices, Hospitals, Health, Health Technology, Personalized medicine, Partnership, AIR, History, GE HealthCare, Digital, Hospital, Patient, Radiology

GE HealthCare (Nasdaq: GEHC), a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, and MedQuest Associates (MedQuest), a leading owner, operator, and manager of outpatient diagnostic imaging facilities, today announced a three-year collaboration to deliver excellence in patient care by providing access to innovative technologies from GE HealthCare and the infrastructure and resources from MedQuest that are needed to optimize multi-site outpatient imaging networks for success.

Key Points: 
  • GE HealthCare (Nasdaq: GEHC), a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, and MedQuest Associates (MedQuest), a leading owner, operator, and manager of outpatient diagnostic imaging facilities, today announced a three-year collaboration to deliver excellence in patient care by providing access to innovative technologies from GE HealthCare and the infrastructure and resources from MedQuest that are needed to optimize multi-site outpatient imaging networks for success.
  • Innovative care models and emerging technologies in outpatient imaging are vital to boosting operational efficiency and expanding access, helping ensure top-tier patient care.
  • MedQuest’s model of joint ventures with health systems, coupled with GE HealthCare’s innovative technologies, will help deploy emerging imaging solutions, including solutions to support Theranostics, into the ambulatory setting.
  • “GE HealthCare is excited to provide advanced technologies and digital tools to enable clinicians to make faster, more informed decisions through intelligent data and smart devices to help improve patient outcomes,” said Jason Schneck, President, U.S. & Canada Imaging, GE HealthCare.

Lifescale Analytics to Exhibit at the HIMSS Global Health Conference & Exhibition

Retrieved on: 
Thursday, February 8, 2024
Consultant, Supply chain, Data governance, Cause of action, Predictive analytics, Remote patient monitoring, Data stream, Conference, Data science, AI, Orange County Convention Center, Machine learning, CIO, Drone, Nutrition, LSA, HIMSS, Patient satisfaction, Personalized medicine, Roger Hawkins (drummer)

"Our ability to partner with healthcare organizations and take their Historically Valuable Data to make it Immediately Actionable significantly improves outcomes in Patient Satisfaction, Physician Burnout, Supply Chain, and Precision Medicine across the entire continuum of care. Lifescale Analytics provides an invaluable roadmap for our customers to facilitate Data Maturity with our expertise in Data Governance, Data Science and Engineering, GIS Data, Patient Data, AI & Machine Learning--all to support clinical workflows. Drones, Surgical Robots, Remote Patient Monitoring, Predictive Analytics and Nutrition are all areas that when addressed, drive a healthier population," said Jay Mervis, Director of Sales, Lifescale Analytics. 

Key Points: 
  • ROSEVILLE, Minn., Feb. 8, 2024 /PRNewswire/ -- Lifescale Analytics (LSA) a certified Woman-Owned Small Business that provides specialized expertise in data and analytics will be exhibiting and attending at the HIMSS (Healthcare Information and Management Systems Society) Global Health Conference & Exhibition.
  • The HIMSS Conference will be held in Orlando, FL at the Orange County Convention Center on March 11-15, 2024.
  • The HIMSS Conference brings together professionals of the healthcare community from around the world.
  • Drones, Surgical Robots, Remote Patient Monitoring, Predictive Analytics and Nutrition are all areas that when addressed, drive a healthier population," said Jay Mervis, Director of Sales, Lifescale Analytics.

Exscientia Initiates Clinical Study to Further Evaluate Functional Precision Medicine Platform in Cancer Patients

Retrieved on: 
Wednesday, February 7, 2024
Oncology, Health, Technology, Clinical Trials, Artificial Intelligence, Pharmaceutical, Biotechnology, Personalized medicine, Bone marrow, Acute leukemia, EVP, Patient, Ovarian cancer, AML, Blood, Deep learning, Medicine, Pharmaceutical industry

The EXCYTE-2 study will collect blood and bone marrow samples from first-line patients with AML, with an option to expand to second-line patients.

Key Points: 
  • The EXCYTE-2 study will collect blood and bone marrow samples from first-line patients with AML, with an option to expand to second-line patients.
  • The EXCYTE-2 study builds on other previously initiated precision medicine focused studies, including EXALT-1 and EXCYTE-1.
  • EXCYTE-2 will leverage the progress the company has made on its AI-driven precision medicine platform since the EXALT-1 trial was completed and will specifically evaluate earlier stage patient populations.
  • “A robust correlation between our platform’s results and clinical outcomes has the potential to change clinical practice for the benefit of AML patients.”